-
公开(公告)号：US11717567B2
公开(公告)日：2023-08-08
申请号：US17194779
申请日：2021-03-08
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： SangKon Oh , Sandra Zurawski , Gerard Zurawski
IPC: A61K39/12 , A61K39/395 , C07K14/025 , C07K16/28 , C07K14/005 , C12N7/00 , A61K39/00
CPC classification number: A61K39/12 , A61K39/395 , A61K39/3955 , A61K39/39541 , C07K14/005 , C07K16/2878 , C12N7/00 , A61K2039/505 , A61K2039/53 , A61K2039/55511 , A61K2039/585 , A61K2039/6056 , A61K2039/70 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2319/74 , C07K2319/91 , C12N2710/20034
Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
-
公开(公告)号：US20170106051A1
公开(公告)日：2017-04-20
申请号：US15311572
申请日：2015-05-15
Applicant: Baylor Research Institute
Inventor： SangKon Oh , Sandra Zurawski , Hyemee Joo , Gerard Zurawski
CPC classification number: A61K38/2066 , A61K39/0008 , A61K2039/505 , A61K2039/54 , A61K2039/57 , C07K14/5428 , C07K16/2851 , C07K16/2878 , C07K2317/24 , C07K2317/40 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2319/00
Abstract: Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.
-
公开(公告)号：US09567401B2
公开(公告)日：2017-02-14
申请号：US14165400
申请日：2014-01-27
Applicant: Baylor Research Institute
Inventor： Jacques F. Banchereau , Gerard Zurawski , Sandra Zurawski , SangKon Oh
IPC: A61K39/395 , C07K16/28 , C07K14/005 , A61K39/00
CPC classification number: C07K16/2878 , A61K39/00 , A61K2039/6056 , C07K14/005 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/74 , C07K2317/80 , C07K2319/00 , C12N2740/16222 , C12N2740/16322
Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
Abstract translation: 本发明包括用于表达，分泌和使用用作例如疫苗和抗原递送载体的用于将抗原递送至抗原呈递细胞的组合物和方法。 在一个实施方案中，载体是抗CD40抗体或其片段，以及与抗-CD40抗体或其片段（包括人源化抗体）连接的一个或多个抗原肽。
-
公开(公告)号：US09339556B2
公开(公告)日：2016-05-17
申请号：US13927437
申请日：2013-06-26
Applicant: Baylor Research Institute
Inventor： Jacques F. Banchereau , SangKon Oh , Gerard Zurawski , Sandra Zurawski , Dapeng Li
CPC classification number: A61K47/48369 , A61K2039/5154 , A61K2039/55516 , C07K16/28 , C07K2317/92 , C07K2319/01 , C07K2319/33
Abstract: The present invention includes compositions and methods for targeting the LOX-1 receptor on immune cells and uses for the anti-LOX-1 antibodies.
-
公开(公告)号：US11957734B2
公开(公告)日：2024-04-16
申请号：US17301123
申请日：2021-03-25
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： SangKon Oh , Sandra Zurawski , Hyemee Joo , Gerard Zurawski
CPC classification number: A61K38/2066 , A61K39/0008 , C07K14/5428 , C07K16/2851 , C07K16/2878 , A61K2039/505 , A61K2039/54 , A61K2039/57 , C07K2317/24 , C07K2317/40 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2319/00
Abstract: Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.
-
Patent Agency Ranking
公开(公告)号：US20220340670A1
公开(公告)日：2022-10-27
申请号：US17687971
申请日：2022-03-07
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： Jacques F. Banchereau , Gerard Zurawski , Sandra Zurawski , SangKon Oh
IPC: C07K16/28 , C07K14/005
Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
-
公开(公告)号：US10286058B2
公开(公告)日：2019-05-14
申请号：US15111357
申请日：2015-01-13
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： SangKon Oh , Sandra Zurawski , Gerard Zurawski
IPC: A61K39/12 , A61K39/395 , C07K14/025 , C07K16/28 , C07K14/005 , C12N7/00 , A61K39/00
Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV 16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
-
公开(公告)号：US10167339B2
公开(公告)日：2019-01-01
申请号：US15501526
申请日：2015-08-03
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： Yong-Jun Liu , Sandra Zurawski , SangKon Oh , Shino Hanabuchi , Haruyuki Fujita , Hideki Ueno , Patrick Blanco , Hyemee Joo
IPC: A61K39/395 , A61K39/00 , C07K16/28
Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-α and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.
-
公开(公告)号：US20150064205A1
公开(公告)日：2015-03-05
申请号：US14484599
申请日：2014-09-12
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： SangKon Oh , Jacques F. Banchereau , Gerard Zurawski , Hideki Ueno , Ling Ni
CPC classification number: C07K16/2851 , A61K39/12 , A61K39/145 , A61K39/385 , A61K39/39 , A61K47/36 , A61K47/42 , A61K2039/55572 , A61K2039/6056 , C07K2317/76 , C07K2319/035 , C12N2760/16134
Abstract: Compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses are disclosed herein. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of pathogenic infections.
Abstract translation: 本文公开了用于增强Th1 / Th17细胞应答和降低Th2细胞应答的组合物和方法。 在各种实施方案中，本发明描述了在含有Dectin-1的人树状细胞中激活人树突状细胞的活化和增强抗原特异性T细胞应答，所述树突细胞包含与一种或多种抗原融合的抗Dectin-1特异性抗体或其片段 。 还可以包括TLR2配体以增强T细胞反应的活化和增强。 此外，本发明还包括基于本文所述的用于治疗病原体感染的组合物的方法。
-
公开(公告)号：US10993990B2
公开(公告)日：2021-05-04
申请号：US15311572
申请日：2015-05-15
Applicant: Baylor Research Institute
Inventor： SangKon Oh , Sandra Zurawski , Hyemee Joo , Gerard Zurawski
Abstract: Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.
-
-
-
-
-
-
-
-
-
Search Results
31
records
(took 0.024 seconds)
